Yellow plaque (cutaneous xanthoma) - Symptoms, Causes, Treatment & Prevention

Overview

A yellow plaque, medically known as a cutaneous xanthoma, is a benign skin lesion composed of lipid‑laden macrophages (foam cells) that accumulate in the dermis or subcutis. The plaques appear as well‑defined, yellow‑to‑orange, sometimes slightly raised patches that most often develop on the elbows, knees, hands, feet, and around the eyes (xanthelasma). While the lesions themselves are harmless, they are often a visible clue that underlying lipid metabolism is disturbed.

Who it affects: Xanthomas can appear at any age, but the pattern varies with the underlying cause. Familial hypercholesterolemia (FH) often presents in children or early adulthood, whereas xanthomas linked to diabetes, obesity, or liver disease tend to arise later in life.

Prevalence: Exact population numbers are difficult to capture because many lesions are asymptomatic and go unnoticed. However, epidemiologic studies estimate that visible xanthomas occur in 1–2 % of adults with dyslipidemia and in up to 15 % of patients with untreated familial hypercholesterolemia ^[1][2].

Symptoms

Cutaneous xanthomas can present with a range of dermatologic findings. Not every patient experiences all of the following:

• Yellow‑orange plaque: Well‑demarcated, flat or slightly raised patches; color may deepen with sunlight exposure.
• Location‑specific patterns:
  • Tendon xanthomas – over Achilles tendon, extensor tendons of the hands.
  • Palmar/xanthoma striatum – linear streaks on the palms.
  • Xanthelasma – around the eyelids.
• Texture: Usually soft to firm; may feel slightly papular when pressed.
• Size: From a few millimeters to several centimeters; lesions can coalesce into larger plaques.
• Absence of pain or itching: Most xanthomas are asymptomatic, which is why they are often first noticed incidentally or during a routine skin exam.
• Associated systemic signs: In cases linked to severe hyperlipidemia, patients may have a history of early‑onset cardiovascular disease, pancreatitis, or gallstones.

Causes and Risk Factors

Yellow plaques are not a disease themselves; they are a manifestation of lipid dysregulation. The main etiologies include:

Primary (Genetic) Causes

• Familial Hypercholesterolemia (FH): Autosomal dominant mutations in the LDLR, APOB, or PCSK9 genes lead to markedly elevated LDL‑C. Tendon xanthomas are classic.
• Familial Dysbetalipoproteinemia (Type III hyperlipoproteinemia): ApoE2/E2 genotype causes remnant lipoprotein accumulation, producing tubero‑eruptive and palmar xanthomas.
• Familial Hypertriglyceridemia: Very high triglycerides can cause eruptive xanthomas (tiny yellow papules) that sometimes merge into plaques.

Secondary (Acquired) Causes

• Uncontrolled Diabetes Mellitus: Especially type 2; glycation of lipoproteins enhances foam‑cell formation.
• Obesity and Metabolic Syndrome: Elevated triglycerides and low HDL‑C increase risk.
• Liver disease: Cirrhosis or cholestasis can raise plasma cholesterol, leading to xanthelasma.
• Nephrotic syndrome: Loss of proteins stimulates hepatic lipoprotein synthesis.
• Medications: High‑dose glucocorticoids, antiretroviral therapy, or certain retinoids may raise lipid levels.

Risk Modifiers

• Family history of early heart attack or known hyperlipidemia.
• Smoking, sedentary lifestyle, and a diet high in saturated fats.
• Ethnicity – FH is more prevalent in South‑African Afrikaners and French‑Canadian populations.

Diagnosis

Because skin lesions can mimic many other conditions, a systematic approach is essential.

Clinical Examination

• Visual inspection of color, distribution, and texture.
• Palpation to assess firmness and depth.
• Documentation of size and number with photography for monitoring.

Laboratory Tests

1. Lipid profile: Fasting total cholesterol, LDL‑C, HDL‑C, triglycerides. In FH, LDL‑C is often >190 mg/dL in adults.
2. Liver function tests (LFTs): To rule out cholestasis.
3. Renal panel: Creatinine, urine protein quantification – helpful for nephrotic syndrome.
4. Hemoglobin A1c: Screens for diabetes.
5. Genetic testing: Targeted sequencing of LDLR, APOB, PCSK9, or APOE when FH or dysbetalipoproteinemia is suspected.

Imaging & Histology

• Dermoscopic examination: Shows yellow‑orange structures without vascular patterns.
• Skin biopsy (rarely needed): Histology reveals lipid‑filled foam cells within the dermis, confirming the diagnosis.
• Ultrasound of tendons: Detects tendon thickening in FH, useful when plaques are not obvious.

Treatment Options

Treatment goals are twofold: (1) remove or reduce the skin lesions for cosmetic or functional reasons, and (2) correct the underlying lipid abnormality to prevent cardiovascular complications.

Medical Management

• Statins: First‑line agents (e.g., atorvastatin, rosuvastatin) reduce LDL‑C by 30‑55 % and often lead to regression of xanthomas over months to years.
• Ezetimibe: Adds ~15‑20 % LDL‑C reduction when combined with a statin.
• PCSK9 inhibitors (evolocumab, alirocumab):** For patients with FH or statin intolerance; can lower LDL‑C >60 % and may shrink plaques dramatically ^[3].
• Fibrates (fenofibrate, gemfibrozil):** Primarily lower triglycerides; useful in eruptive xanthomas.
• Niacin: Lowers VLDL and raises HDL‑C, but side‑effects limit long‑term use.
• Omega‑3 fatty acids: Adjunct for hypertriglyceridemia.

Procedural Options

• Laser therapy (CO₂ or Er:YAG): Effective for superficial plaques and especially xanthelasma; multiple sessions may be required.
• Radiofrequency ablation: Offers precise removal with minimal scarring.

Lifestyle Interventions

• Adopt a heart‑healthy diet (Mediterranean style): plenty of fruits, vegetables, whole grains, fatty fish; limit saturated fats, trans‑fats, and cholesterol.
• Engage in at least 150 minutes of moderate‑intensity aerobic activity per week (American Heart Association recommendation).
• Maintain a healthy body weight; a 5‑% weight loss can reduce triglycerides by 10‑15 %.
• Quit smoking and limit alcohol intake (< 2 drinks/day for men, < 1 for women).
• Regular follow‑up lipid panels every 3–12 months, depending on risk.

Living with Yellow Plaque (Cutaneous Xanthoma)

Even after successful treatment, patients may need ongoing strategies to keep lesions from recurring.

• Skin care: Use gentle, fragrance‑free moisturizers; avoid harsh scrubs that could traumatize plaques.
• Sun protection: UV exposure can deepen color; apply broad‑spectrum SPF 30+ daily.
• Regular monitoring: Keep a log of lesion size and photograph changes every 6–12 months.
• Cardiovascular vigilance: Because xanthomas are markers of high lipid burden, adhere to blood pressure, glucose, and weight goals.
• Support groups: Connecting with FH or lipid‑disorder communities can improve adherence and emotional well‑being.

Prevention

Prevention focuses on lipid control before plaques develop.

1. Screen early: Universal lipid screening at ages 9–11 and again at 17–21, per American Academy of Pediatrics guidelines ^[4]. Family‑history‑driven testing can start even earlier.
2. Treat dyslipidemia promptly: Initiate statin therapy in FH children ≥8 years (or younger if LDL‑C >190 mg/dL with family history of early heart disease).
3. Adopt a sustainable diet and activity plan: The Mediterranean diet reduces LDL‑C by ~10 % and triglycerides by ~15 %.
4. Avoid iatrogenic lipid elevation: Discuss alternative medications with your provider if you require long‑term steroids or protease inhibitors.

Complications

If the underlying lipid disorder remains uncontrolled, several serious outcomes may arise:

• Accelerated atherosclerosis: Early‑onset coronary artery disease, peripheral arterial disease, and stroke.
• Pancreatitis: Very high triglycerides (>1000 mg/dL) can precipitate acute pancreatitis.
• Tendon dysfunction: Large tendon xanthomas may limit joint range of motion or cause discomfort during activity.
• Psychosocial impact: Visible plaques, especially on the face (xanthelasma), can affect self‑esteem and quality of life.
• Rare malignant transformation: While xanthomas are benign, chronic inflammation can rarely predispose to skin cancers in the same area; routine skin checks are advised.

When to Seek Emergency Care

References:

1. Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019.
2. Nordestgaard BG, et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population. J Clin Endocrinol Metab. 2020;105(10):3422‑3433. doi:10.1210/clinem/dgz123.
3. Raal FJ, et al. PCSK9 inhibition with evolocumab in homozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1022‑1031.
4. American Academy of Pediatrics. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics. 2016.